Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kathleen Haden"'
Autor:
Ileana S Mauldin, Craig L Slingluff, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Kelly T Smith, Nikole Varhegyi, William W Grosh, Kathleen Haden, Lynn T Dengel, Elizabeth M Gaughan, Varinder Kaur, Rick D Vavolizza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background A vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe, immunogenic, and clinically active. A phase I/II trial was designed to evaluate safety and immunogenicity of 6MHP vaccines plus programmed deat
Externí odkaz:
https://doaj.org/article/1a506d69a6074192a111b9cc4c3d7259
Autor:
Patrick Hwu, Jason Roszik, Gina R Petroni, Walter C Olson, Kimberly A Chianese-bullock, Kelly T Smith, Nikole Varhegyi, Elizabeth Gaughan, Mark Smolkin, Sacha Gnjatic, Nolan A Wages, Emily H Hall, Kathleen Haden, Sapna P Patel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background We performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund’s adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7/8 (resiquimod). We hypothesi
Externí odkaz:
https://doaj.org/article/51b27bff54f64a76a32d944873fe4395
Autor:
Kelly T Smith, Nikole Varhegyi, Nolan A Wages, Emily H Hall, Kathleen Haden, Craig L Slingluff, Jr., Lynn T Dengel, Anna Dickinson, Caroline Reed, Elizabeth M Gaughan, Varinder Kaur, Nadejda V Galeassi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Background Peptide vaccines designed to stimulate melanoma-reactive CD4+ T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incompl
Externí odkaz:
https://doaj.org/article/0f1633d6e6534feb8dfa73c25184c8d5
Autor:
Walter C. Olson, Sacha Gnjatic, Craig L. Slingluff, Emily H. Hall, Kelly T. Smith, Kathleen Haden, Mark E. Smolkin, Nolan A. Wages, Gina R. Petroni, Kimberly A. Chianese-Bullock, Patrick Hwu, Jason Roszik, Elizabeth M. Gaughan, Sapna Pradyuman Patel, Nikole Varhegyi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundWe performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund’s adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7/8 (resiquimod). We hypothesiz
Autor:
Rick D Vavolizza, Gina R Petroni, Ileana S Mauldin, Kimberly A Chianese-Bullock, Walter C Olson, Kelly T Smith, Lynn T Dengel, Kathleen Haden, William W Grosh, Varinder Kaur, Nikole Varhegyi, Elizabeth M Gaughan, Craig L Slingluff
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e005424
BackgroundA vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe, immunogenic, and clinically active. A phase I/II trial was designed to evaluate safety and immunogenicity of 6MHP vaccines plus programmed death
Autor:
Nadejda V. Galeassi, Caroline Reed, Varinder Kaur, Kathleen Haden, Walter C. Olson, Kimberly A. Chianese-Bullock, Anna Dickinson, Emily H. Hall, Kelly T. Smith, William W. Grosh, Nolan A. Wages, Donna H. Deacon, Gina R. Petroni, Craig L. Slingluff, Nikole Varhegyi, Mark E. Smolkin, Lynn T. Dengel, Elizabeth M. Gaughan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
BackgroundPeptide vaccines designed to stimulate melanoma-reactive CD4+ T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomple
Autor:
Kimberly A. Chianese-Bullock, Elizabeth M. Gaughan, Lynn T. Dengel, Varinder Kaur, Ileana S. Mauldin, Craig L. Slingluff, Kelly T. Smith, Kathleen Haden, William W. Grosh, Walter C. Olson
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A421-A421
BackgroundA multipeptide vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe and immunogenic and has clinical activity. A phase I/II trial was designed to evaluate safety and immunogenicity of 6MHP vaccines pl
Autor:
Rebecca C. Obeng, Nikole Varhegyi, Kimberly A. Chianese-Bullock, Gina R. Petroni, Geoffrey R. Weiss, Elizabeth M. Gaughan, Angela L. Ambakhutwala, Emily H. Hall, Kelly T. Smith, Mark Cobbold, Victor H. Engelhard, Kara L. Cummings, Amanda M. Lulu, Paisley T. Myers, Mark E. Smolkin, Nico Buettner, Craig L. Slingluff, Jeffrey Shabanowitz, Kathleen Haden, Donald F. Hunt, Keira E. Mahoney
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundPhosphorylated peptides presented by MHC molecules represent a new class of neoantigens expressed on cancer cells and recognized by CD8 T-cells. These peptides are promising targets for cancer immunotherapy. Previous work identified an HLA-
Autor:
Wendy F. Cohn, Beverely Turner, Tracee Martin-Fries, Marguerite C. Lippert, Susan Miesfeldt, Stephanie M Clark, Susan M. Jones, Kathleen Haden
Publikováno v:
Urology. 55(1)
Objectives. Little is known about the attitudes of men unselected for a family history for prostate cancer concerning genetic testing for prostate cancer risk or genetic testing for inherited cancer predisposition. To explore this, we examined the in